Drug resistance during Indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites

Journal of Virology

Volumn 71, Issue 9, 1997, Pages 6662-6670

  Zhang, Yi Ming ^a   Imamichi, Hiromi ^a   Imamichi, Tomozumi ^a   Lane, H Clifford ^b   Falloon, Judith ^b   Vasudevachari, M B ^a   Salzman, Norman P ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; INDINAVIR; INTERLEUKIN 2; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0030769354     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.9.6662-6670.1997     Document Type: Article

References (35)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Robson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Coffin, J. M. 1995. HIV population dynamics in vivo:implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
3. Collier A. C., R. W. Coombs, D. A. Schoenfeld, R. L. Bassett. J. Timpone, A. Baurch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, und L. Corey for the AIDS Clinical Group. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1011-1017.
4. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
5. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374:569-571.
6. Croteau, G., L. Doyon, D. Thibeauly, G. Mckercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitor. J. Virol. 71:1089-1096.
7. Darke, P. L., and J. R. Huff. 1994. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol. 25:399-454.
8. Dewar, R. L., H. C. Highbarger, M. D. Sarmiento, J. A. Todd, M. B. Vasudevachari, R. T. Davey, J. A. Kovacs, N. P. Salzman, H. C. Lane, and M. S. Urdea. 1994. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1172-1179.
9. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Piloteand, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
10. Embretson, J., M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz, and A. T. Haase. 1993. Massive convert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 362:359-362.
11. Falloon, J., C. Owen, J. Metcalf, G. Fyfe, H. C. Lane, and NIAID-Clinlcal Center Intramural AIDS Program. 1996. Indinavir and interleukin-2 in HIV:one year follow-up, abstr. I108. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Faulkner, D. V., and J. Jurka. 1988. Multiple aligned sequence editor (MASE). Trends Biochem. Sci. 13:321-322.
13. Greer, J., J. W. Erickson, J. J. Baldwin, and M. D. Varney. 1994. Application of the three-dimensional structures of protein target molecules in structurebased drug design. J. Med. Chem. 37:1035-1054.
14. Guiseppe, P., C. Graziosi, J. F. Demarest, L. Butinl, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinical latent stage of disease. Nature (London) 362:355-358.
15. Gulick R, J. Mellors, D. Havlir, J. Eron, C. Gonzalez, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohn, R. Chiou, P. Deutsch, E. Emini, and J. Chodakewitz. 1996. Potent and sustained antiretroviral activity of Indinavir in combination with zidovudine and lamivudine, abstr. LB7. In Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C. Infectious Diseases Society of America, National Institutes of Health, and Centers for Disease Control and Prevention.
16. Haertle, T., C. J. Carrera, D. B. Wesson, L. C. Sowers, D. D. Richman, and D. A. Carson. 1988. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J. Biol. Chem. 263:5870-5875.
17. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/ LAV in HTLV-1 -carrying cells MT-2 und MT-4 and application in a plaque assay. Science 229:563-566.
18. Hoen B., M. Harzic, H. F. Fleury, E. Gomard. L. Beauvals, J. P. Chauvin, and D. Sereni. 1997. ANRS053 trial of zidovudine (ZDV), lamivudine (3TC) and ritonavir combination in patients with symptomatic primary HIV-1 infection:preliminary results, abstr. 232. In Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C. Infectious Diseases Society of America, National Institutes of Health, and Centers for Disease Control and Prevention. 18a.Imamichi, H. Unpublished results.
19. King, R. W., S. Garber, D. L. Winslow, C. D. Reid, L. T. Bacheler, E. Anton, and M. J. Otto. 1995. Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chem. Chemother. 6:80-88.
20. Korber, B., and G. Myers. 1992. Signature pattern analysis:a method for assessing viral sequence relatedness. AIDS Res. Hum. Retroviruses 8:1549-1560.
21. Lech, W. J., G. Wang, Y. L. Yang, Y. Chee, K. Dorman, D. McCrae, L. C. e Lazzeroni, J. W. Erickson, J. S. Sinsheimer, and A. H. Kaplan. 1996. In vivo sequence diversity of the proiense of human immunodeficiency virus type 1:presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043.
22. Markowitz, M., Y. Cao, M. Vesanen, A. Talal, D. Nixon, A. Hurley, R. O'Donovan, P. Racz, K. Tenner-Racz, and D. D. Ho. 1997. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor, abstr. LB8. In Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C. Infectious Diseases Society of America, National Institutes of Health and Centers for Disease Control and Prevention.
23. Markowitz M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. L. Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
24. Mellors, J. W., B. A. Larder, and R. F. Schinazi. 1995. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 3:8-13.
25. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavsky, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, D. J. Kempf. 1996. Ordered accumulation of mutation in HIV protease confers resistance to ritonavir. Nature Med. 2:760-766.
26. Myers, G., B. Korber, S. Wain-Hobson, K.-T. Jeang, L. E. Henderson, and G. N. Pavlakis. 1994. Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, N.M.
27. Rose, R. E., Y.-F. Gong, J. A. Greytok, C. M. Bechtold, B. J. Terry, B. S. Robinson, M. Alam, R. J. Colonno, and P.-F. Lln. 1996. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
28. Sakseka, K., E. Muchmore, M. Girard, P. Fultz, and D. Baltimore. 1993. High level load in lymph node and latent human immunodeficieney virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J. Virol. 67:7423-7427.
29. Schmit J-C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter, E. D. Clercq, und A.-M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
30. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTALW:improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:1673-4680.
31. Vacca J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524:an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
32. Vella, S., C. Galluzzo, G. Giannini, M. F. Pirillo, I. Duncan, H. Jocobsen, M. Andreoni, L. Sarmati, and L. Ercoli. 1996. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy:CD4 lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res. 29:91-93.
33. Winslow, D. L., S. Stack, R. King, H. Scarnati, A. Bincsik, and M. J. Otto. 1995. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res. Hum. Retroviruses 11:107-113.
34. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-585.
35. Yamaguchi, K., and R. A. Byrn. 1995. Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations. Biochim. Biophys. Acta 1253:136-140.